Genzyme Gets FDA Warning Letter On French Thymoglobulin Plant
This article was originally published in The Pink Sheet Daily
Biotech received similar letter in 2004 questioning quality control practices.
You may also be interested in...
Manufacturing issues plague Genzyme’s Thymoglobulin as its sales grow and firm studies additional indications.
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.